It’s a familiar story: Midway through their college career, a Stanford student gets a bright idea, drops out and founds a startup.
In 2003, 19-year-old Elizabeth Holmes left the Farm to build Theranos, a biotech company that claimed to have the technology to extract millions of test results from one drop of blood. At its peak in the mid 2010s, Theranos was valued at over $9 billion. Holmes became a corporate icon; the classic college dropout-turned-entrepreneur. But behind the sky-high valuation and Forbes covers was technology that simply did not work.
After a 2015 Wall Street Journal (WSJ) investigation revealed Theranos was using third-party blood analyzers and producing faulty results, Holmes’ charade began to unravel. In 2022, she was found guilty of four counts of wire fraud and one count of attempting to commit wire fraud and sentenced to 11 years in prison.
In October, the release of Nathan Fielder and Lance Oppenheim’s “You Can See Everything” (2026) thrust the disgraced CEO back into the spotlight. In the weeks following the release of the documentary, which chronicles the time leading up to and during Holmes’ incarceration, the question flitting around Green Library, CoHo and more was “Have you seen the Elizabeth Holmes documentary?”
Evidently, Holmes’ name still commands attention, especially at Stanford, her “alma mater.” She has become something of an icon on campus, with many donning a black turtleneck and blonde wig for Halloween. But what does the reception of the film say about the legacy Elizabeth Holmes left behind?
Members of the Stanford community shared their opinion on both the film and Holmes herself. Kyle Gerstel ’29, president of Stanford Students in Entertainment (SSIE) and a contributor to The Daily, found the film riveting, but mostly on account of Nathan Fielder.
“‘You Can See Everything’ really does feel like a perfect evolution of [Fielder’s] knack for creative storytelling,” Gerstel said. He also appreciates how, by rendering viewers uncertain of what is false and what is real, Fielder’s documentary “get[s] us to think about the narratives in our lives” pertaining to a “subject [Holmes] that is endlessly fascinating.”
Other students, however, were more interested in the depiction of Holmes in the film. Miles Bliey ’27 said that the movie left him “on the fence about whether she was guilty or innocent,” but after doing research on Holmes’ crimes, decided that its depiction of her was “too generous.” He also commented on the numerous Elizabeth Holmes costumes he saw on Halloween: “People don’t really take her seriously,” he said, adding that Holmes “is not seen as a cautionary tale” despite the startup culture on campus.
The conversation of Holmes’ legacy and the documentary’s effects on it extends beyond the student body. John Ioannidis, a medical school professor who specializes in evidence-based medicine and meta-research, was among the earliest to publicly challenge Theranos. In February 2015, prior to the WSJ investigation, he published a paper in the Journal of American Medical Association criticizing Theranos for operating in “stealth mode” and exposing the fact that the company had not published or cited peer-reviewed research supporting its technology.
Contrary to those who view the documentary as purely cinema, Ioannidis believes there are more serious implications to Holmes’ recent surge in fame.
“Honestly, it feels a little embarrassing that this is even becoming a documentary,” he told The Daily. He also said the film “reinforces the wrong narratives and perspectives, as it makes people think [Holmes] is a one-off bad apple.” In reality, Ioannidis said, there are many other startups of a “similar phenotype” to Theranos.
Ioannidis acknowledged that while startup culture can fuel innovation, the “temptation to cut corners, violate rules and make extravagant claims that are out of proportion with the evidence” is endemic within it.
After his paper on Theranos, Ioannidis published several other papers examining startups with a valuation of at least $1 billion.
“About half of them don’t disclose anything [about their scientific basis], or very little,” he said. “If anything, the ones that had the highest evaluations were disclosing less, and sharing and publishing less.”
So should we transform Holmes into a comical figure; a film character whose Steve Jobs getup we satirize for frat parties? Or does her story warrant more critical consideration of the pitfalls of ambition? In the wake of “You Can See Everything,” one thing is for certain. At Stanford — a place knee-deep in the murky waters of Silicon Valley and venture capital — Holmes’ influence is far from diminished.